Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more
Monte Rosa Therapeutics Inc (GLUE) - Total Assets
Latest total assets as of September 2025: $459.84 Million USD
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) holds total assets worth $459.84 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Monte Rosa Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Monte Rosa Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Monte Rosa Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Monte Rosa Therapeutics Inc's total assets of $459.84 Million consist of 86.0% current assets and 14.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.1% |
| Accounts Receivable | $173.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Monte Rosa Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Monte Rosa Therapeutics Inc's current assets represent 86.0% of total assets in 2024, a decrease from 88.0% in 2019.
- Cash Position: Cash and equivalents constituted 51.1% of total assets in 2024, down from 54.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Monte Rosa Therapeutics Inc Competitors by Total Assets
Key competitors of Monte Rosa Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Monte Rosa Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Monte Rosa Therapeutics Inc generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Monte Rosa Therapeutics Inc is currently not profitable relative to its asset base.
Monte Rosa Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.54 | 6.03 | 1.49 |
| Quick Ratio | 6.54 | 6.03 | 1.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $340.37 Million | $ 209.57 Million | $ 14.32 Million |
Monte Rosa Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Monte Rosa Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.98 |
| Latest Market Cap to Assets Ratio | 1.69 |
| Asset Growth Rate (YoY) | 44.4% |
| Total Assets | $438.73 Million |
| Market Capitalization | $743.29 Million USD |
Valuation Analysis
Above Book Valuation: The market values Monte Rosa Therapeutics Inc's assets above their book value (1.69 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Monte Rosa Therapeutics Inc's assets grew by 44.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Monte Rosa Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Monte Rosa Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $438.73 Million | +44.44% |
| 2023-12-31 | $303.75 Million | -11.28% |
| 2022-12-31 | $342.39 Million | -6.54% |
| 2021-12-31 | $366.33 Million | +641.89% |
| 2020-12-31 | $49.38 Million | +345.09% |
| 2019-12-31 | $11.09 Million | -- |